IPO: NexImmune Deploys Synthetic Dendritic Cells To Fight Cancer
NexImmune, Inc, based in Gaithersburg, MD, is a clinical-stage biotechnology company developing immunotherapies that employ the body’s own T cells to generate a specific, potent and durable immune response that mimics natural biology. The company’s nanotechnology platform was originally developed at Johns Hopkins University. The backbone of the company’s approach is its Artificial Immune Modulation, … Read more